Found: 26
Select item for more details and to access through your institution.
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 6, p. 1253, doi. 10.1007/s40121-024-00970-x
- By:
- Publication type:
- Article
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 3, p. 521, doi. 10.1007/s40121-024-00931-4
- By:
- Publication type:
- Article
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).
- Published in:
- Infectious Diseases & Therapy, 2023, v. 12, n. 12, p. 2691, doi. 10.1007/s40121-023-00882-2
- By:
- Publication type:
- Article
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
- Published in:
- Infectious Diseases & Therapy, 2023, v. 12, n. 9, p. 2269, doi. 10.1007/s40121-023-00861-7
- By:
- Publication type:
- Article
The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 20, p. 11286, doi. 10.3390/ijms222011286
- By:
- Publication type:
- Article
Altered Expression of Insulin Receptor Isoforms in Breast Cancer.
- Published in:
- PLoS ONE, 2011, v. 6, n. 10, p. 1, doi. 10.1371/journal.pone.0026177
- By:
- Publication type:
- Article
Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 5, p. 1167, doi. 10.1007/s00262-021-03065-5
- By:
- Publication type:
- Article
CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.
- Published in:
- Pediatric Transplantation, 2014, v. 18, n. 2, p. 166, doi. 10.1111/petr.12216
- By:
- Publication type:
- Article
Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
- Published in:
- Arthritis Research & Therapy, 2016, v. 18, p. 1, doi. 10.1186/s13075-016-1021-2
- By:
- Publication type:
- Article
Genomic signatures characterize leukocyte infiltration in myositis muscles.
- Published in:
- BMC Medical Genomics, 2012, v. 5, n. 1, p. 53, doi. 10.1186/1755-8794-5-53
- By:
- Publication type:
- Article
Transforming properties of TC-1 in human breast cancer: Interaction with FGFR2 and β-catenin signaling pathways.
- Published in:
- International Journal of Cancer, 2007, v. 121, n. 6, p. 1265, doi. 10.1002/ijc.22831
- By:
- Publication type:
- Article
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.
- Published in:
- Science Translational Medicine, 2019, v. 11, n. 489, p. N.PAG, doi. 10.1126/scitranslmed.aar6584
- By:
- Publication type:
- Article
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 7, p. 1247, doi. 10.1093/cid/ciac899
- By:
- Publication type:
- Article
Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI‐551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease
- Published in:
- Arthritis & Rheumatology, 2018, v. 70, n. 12, p. 2087, doi. 10.1002/art.40656
- By:
- Publication type:
- Article
Inhibition of Myogenic MicroRNAs 1, 133, and 206 by Inflammatory Cytokines Links Inflammation and Muscle Degeneration in Adult Inflammatory Myopathies.
- Published in:
- Arthritis & Rheumatology, 2014, v. 66, n. 4, p. 1022, doi. 10.1002/art.38292
- By:
- Publication type:
- Article
The Plasma Cell Signature in Autoimmune Disease.
- Published in:
- Arthritis & Rheumatology, 2014, v. 66, n. 1, p. 173, doi. 10.1002/art.38194
- By:
- Publication type:
- Article
Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitroIC<sub>50</sub> values predict SARS‐CoV‐2 neutralising antibody titres.
- Published in:
- Clinical & Translational Immunology, 2024, v. 13, n. 6, p. 1, doi. 10.1002/cti2.1517
- By:
- Publication type:
- Article
IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c<sup>hi</sup>T-bet<sup>+</sup> B cells in SLE.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-03750-7
- By:
- Publication type:
- Article
Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, n. 9, p. 1094, doi. 10.1002/jcph.2054
- By:
- Publication type:
- Article
Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR Study.
- Published in:
- Pulmonary Therapy, 2024, v. 10, n. 1, p. 53, doi. 10.1007/s41030-023-00245-9
- By:
- Publication type:
- Article
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans.
- Published in:
- Science Translational Medicine, 2022, v. 14, n. 635, p. 1, doi. 10.1126/scitranslmed.abl8124
- By:
- Publication type:
- Article
Micro RNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D.
- Published in:
- Pigment Cell & Melanoma Research, 2014, v. 27, n. 2, p. 275, doi. 10.1111/pcmr.12200
- By:
- Publication type:
- Article
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
- Published in:
- Journal of Infectious Diseases, 2023, v. 228, n. 8, p. 1055, doi. 10.1093/infdis/jiad210
- By:
- Publication type:
- Article
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
- Published in:
- Journal of Infectious Diseases, 2023, v. 227, n. 10, p. 1153, doi. 10.1093/infdis/jiad014
- By:
- Publication type:
- Article
Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations.
- Published in:
- Pharmaceutical Medicine, 2017, v. 31, n. 4, p. 217, doi. 10.1007/s40290-017-0192-8
- By:
- Publication type:
- Article
Increased IR-A/IR-B ratio in non-small cell lung cancers associates with lower epithelial-mesenchymal transition signature and longer survival in squamous cell lung carcinoma.
- Published in:
- BMC Cancer, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-2407-14-131
- By:
- Publication type:
- Article